Evaluation of the safety, recovery, half-life, and clinical efficacy of
antithrombin III (human) in patients with hereditary antithrombin III
deficiency. Cooperative Study Group [see comments]
D Menache, JP O'Malley, JB Schorr, B Wagner, C Williams, BM Alving, JO Ballard, SH Goodnight, WE Hathaway and MB Hultin
Blood Services, American Red Cross, National Headquarters, Washington, DC
20006.
Antithrombin III (Human) (AT III) was administered to 18 patients with
documented hereditary AT III deficiency. In eight patients with no ongoing
clinical symptoms of thrombosis, the percent increase per unit AT III
infused per kilogram of body weight ranged from 1.56% to 2.74%, and the
half-life from 43.3 to 77.0 hours. No significant difference was noted
between patients receiving and those not receiving coumarin therapy. In
clinically ill patients, the in vivo recovery was significantly lower and
ranged from 0.64% to 1.90% increase per unit AT III infused/kg. Efficacy of
AT III was evaluated in 13 patients for the prevention or treatment of
thrombosis. AT III was efficacious as assessed by the absence of thrombotic
complications after surgery and/or parturition, and the nonextension and
nonrecurrence of thrombosis in patients exhibiting an acute thrombotic
episode. No side effects were noted. Follow-up studies indicated no
hepatitis B seroconversion and no alanine aminotransferase elevations in
patients who were not transfused with other blood products.
Volume 75,
Issue 1,
pp. 33-39,
01/01/1990
Copyright © 1990 by The American Society of Hematology
